Open company graph database — free web & API
Login

MyCane Technologies Co., Ltd.

マイキャン・テクノロジーズ株式会社MiCAN Technologies, Inc.AliasMican TechnologiesAlias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
5
§01

Basic information

BASIC
Head office
1-36, Goryo Ohara, Nishi-Kyō, Kyoto City, Kyoto University Kiyoshi Venture Plaza
Chief executive
Kazuo Miyazaki
Capital
30,000,000
Employees (non-consolidated)
Employees (consolidated)
Start date
2016-07-01
End date
§02

Websites

1 DOMAINS
§03

Business

10
Provision of research-use erythrocyte-like cellsEvaluation services for pharmaceutical developmentVarious contract testing servicesSale of evaluation kitsEvaluation contract servicesCell-based assay kit development and manufacturing for hyperthermic substancesDevelopment of MylcMAT kit for research useDevelopment of MylcEndo product for LAL marketResearch and development of immortalized monocyte cell linesProviding research services for infection control
§04

Related companies

5 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
MiCAN Technologies EUROPA GmbH
Group Subsidiary
Biolabs Heidelberg
Alliance
Nissui Pharmaceuticals Co., Ltd.
Alliance
RealTech Fund
Shareholder
大阪大学VC
Shareholder
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

73 EVENTS

Selected for the Ministry of Economy, Trade and Industry's 'Advanced Problem-Solving Venture Support Project'Sources

Accepted in the Support System for Venture Companies Solving Unmet Medical Needs of the Ministry of Economy, Trade and IndustrySources

Foundation(Chuo-ku, Tokyo)Sources

Established (Chuo City, Tokyo)Sources

EstablishedSources

Development of red blood-like cells for research of infectious diseases (Mpv cells, first product) with Kyoto University and Nagasaki University, patent applicationSources

Won the Globis Venture Challenge AwardSources

Awarded a grand prize of GLOBIS Venture ChallengeSources

Established a research and development base at Kyoto-University Katsura Venture PlazaSources

Co-developed with Kyoto University and Nagasaki University an erythrocyte-like cell for infectious disease research (first product Mpv cell) and filed a patentSources

Initiated development of a myeloid cell line for virus research (second product Mylc cell)Sources

Started development of myeloid cells for research of viruses (Mylc cells, second product)Sources

Established our research and development base at Kyoto University Kiyoshi Venture Plaza (SME Incubation, Kyoto City)Sources

Expanded the Headquarters and LaboratorySources

Commenced shipment of erythrocyte-like cells (pilot product Mpv cell)Sources

Started release of red blood-like cells (prototype product of Mpv cells)Sources

Filed a patent for a myeloid cell line for virus research (second product Mylc cell) with Osaka University and Kumamoto UniversitySources

Patent application for myeloid cells for research of viruses (Mylc cells, second product) with Osaka University and Kumamoto UniversitySources

Relocated headquarters to within Kyoto University Kiyoshi Venture PlazaSources

Transferred the Headquarters to Kyoto-University Katsura Venture PlazaSources

Selected for Kyoto Industry 21's 'Economic Gardening Project'Sources

Adopted for the Economic Gardening Support Grant supported by KyotoIndustrial Support Organization 21Sources

Selected for the Kyoto Chamber of Commerce and Industry's 'Wisdom Management Contest'Sources

Certified as Management of Wisdom by the Kyoto Chamber of Commerce and IndustrySources

Expanded headquarters and research instituteSources

Signed a joint research agreement with Nissui Pharmaceutical Co., Ltd. regarding culture media for product developmentSources

Signed a collaborative research agreement on the development of culture medium with Nissui Pharmaceutical Co., Ltd.Sources

Commenced shipment of myeloid cell line for virus research (pilot product Mylc cells)Sources

Started release of myeloid cells for research of viruses (prototype product)Sources

Raised 127 million yen through a third‑party allocation of shares to Osaka University VC and others (Series ASP)Sources

Raised \127,000,000 by allocation of shares to third parties including Osaka University Venture Capital Co., Ltd. (series A)Sources

Received the Best Award and Kansai Mirai Bank Award at the 1st Osaka Tech Plan Grand PrixSources

Initiated a joint coronavirus research with Osaka University using Mylc cellsSources

Started collaborative research on corona virus using Mylc cells with Osaka UniversitySources

Selected for AMED's Improved Technology Support in the Virus and Other Infectious Disease Countermeasure Technology Development ProjectSources

elected in Support for Improvement Research, Technology Development Project for Measures to Control Viral Infections, by AMEDSources

Adopted into the New Coronavirus Infection Countermeasure Technology Consolidation Project, won the Excellence Award at the 7th Keishin Regional Entrepreneur Award, and adopted into the Reiwa 2 Strategic Core Technology Advancement Support ProjectSources

Commenced provision of cMylc cells for coronavirus researchSources

Opened Kobe Lab (Kobe Industrial Medical City, Creative Lab Kobe/CLIK)Sources

Raised 189 million yen through a third‑party allocation of shares to RealTech Fund and others (Series A2)Sources

Adopted into NEDO's Research & Development Startup Support Project / Business Development Support for Seed‑stage R&D Startups (STS)Sources

Won the Entrepreneur Category Award at the Kansai NBC New Business Award 2021Sources

Received the Kyoto Small and Medium Enterprise Technology Award 2021 (Reiwa 3) – Outstanding Technology AwardSources

Won the Grand Prize in the Collaboration Category of the 2nd Wisdom‑1 Grand Prix hosted by the Kyoto Chamber of Commerce and IndustrySources

Awarded in the Growth Category of the RealTech Venture of the Year 2022Sources

Awarded “Real Tech Venture of the Year 2022” in the Growth categorySources

Won the Grand Prix in the Collaboration Category of the 2nd Wisdom-1 Grand Prix sponsored by the Kyoto Chamber of Commerce and Industry.Sources

Adopted into the Reiwa 4 Growth‑Type SME R&D Support Project (Go‑Tech Project)Sources

Adopted for the “Go-Tech Project” (R&D Support Project for Growth-oriented Small and Medium Enterprises)Sources

Commenced provision of the MylcMAT Kit (research use) – a fever‑inducing substance evaluation kit using immortalized myeloid cells (Mylc)Sources

MyrcMAT Kit (for research), a kit for evaluation of thermogenic substances using immortalized myeloid cells (Mylc), is now available for testing.Sources

Raised 200 million yen through a third‑party allocation of shares to RealTech Fund and others (Series B)Sources

Raised 200 million yen through third-party allotment to real-tech funds and others (Series B)Sources

Adopted into NEDO's Deep Tech Startup Support Project PCA Phase (Late‑Stage Practical Research & Development)Sources

Selected for NEDO’s Deep Tech Startup Support Project PCA Phase (Practical Application R&D (late stage))Sources

Patent 'Evaluation method for anti-infective drugs, vaccines, etc. using dead monocyte cells and induced cells' registered.Sources

Patent “Evaluation Method for Anti-infective Drugs, Vaccines, etc. Using Monocyte-Derived Immune Cells and Induced Cells” registeredSources

Established a European development office at Biolabs Heidelberg in Heidelberg, Germany.Sources

Started shipping paid prototypes of the thermogenic substance alternative test product (MylcMAT) to Europe.Sources

January 2024 MylcMAT, a fever-inducing substance alternative test product, begins shipping paid prototypes to Europe.Sources

Established a European Development Office at Biolabs Heidelberg in Heidelberg, GermanySources

Raised 100 million yen through J-KISS-style new share warrants to 360ip Japan Fund and others.Sources

Raised ¥100 million through J-KISS-type stock acquisition rights for the 360ip Japan Fund and othersSources

Obtained ISO9001 certification for the design, development, and manufacturing of the thermogenic substance test cell kit.Sources

Design, Development, and Manufacturing of Cell Testing Kits for Fever-Inducing Substances ISO 9001 Certification AchievedSources

Obtained ISO9001 certification for the design, development, and manufacturing of the thermogenic substance test cell kit.Sources

Raised ¥280 million through a third-party allotment of new shares to Mitani Sangyo and others (Series B2)Sources

Established subsidiary MiCAN Technologies EUROPA GmbH in Heidelberg, Germany.Sources

Establishment of Subsidiary MiCAN Technologies EUROPA GmbH in Heidelberg, GermanySources

Selected for NEDO Deep Tech Startup Support Project PCA Phase (practical application R&D) for developing the MylcEndo product for the LAL market using immortalized monocyte cells.Sources

NEDO Deep Tech Startup Support Program PCA Phase (Practical Application R&D) selected for “Development of MylcEndo Products for the LAL Market Using Immortalized Monocyte Cells”Sources

Selected for AMED 'Reiwa 7 (2025) Innovative Pharmaceutical Development Promotion Research Project for Emerging and Reemerging Infectious Diseases – Health Tech Challenge'.Sources

Selected for AMED’s “Fiscal Year 2025 Innovative Drug Development Promotion Research Project for Emerging and Re-emerging Infectious Diseases—Health Tech Challenge”Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information7010001177012
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
マイキャン・テクノロジーズ株式会社
Trade name (kana)
マイキャンテクノロジーズ
Name in English
Corporation type
301
Address
〒615-8245 京都府京都市西京区御陵大原1-36京大桂ベンチャープラザ
Postal code
6158245
Prefecture code
26
City code
111
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2016-07-25
Update date
2019-04-26
Change date
2019-04-16
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
3944768
METI gBizINFO7010001177012
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
7010001177012
Trade name
マイキャン・テクノロジーズ株式会社
Trade name (kana)
マイキャンテクノロジーズ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
京都府京都市西京区御陵大原1-36京大桂ベンチャープラザ
Postal code
6158245
Prefecture
京都府
Prefecture code
26
City or district
京都市西京区
City code
111
Street address
御陵大原1-36京大桂ベンチャープラザ
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2019-04-26
Key information
7010001177012
§09

Sources & updates

SOURCES
↑